Spectral-Domain Optical Coherence Tomography of Preclinical Chloroquine Maculopathy in Egyptian Rheumatoid Arthritis Patients

Table 2

Comparison between the different OCT parameters in both groups.

OCT (μm); Mean ± SD	Chloroquine group	Control group	value
CFT	238.15 ± 22.5	248.2 ± 19.05	0.034
Parafoveal thickness
Superior	310.7 ± 21.64	322.35 ± 12.02	0.004
Inferior	309.05 ± 18.75	319.025 ± 11.3	0.005
Nasal	311.45 ± 14.9	320.05 ± 11.39	0.005
Temporal	299.025 ± 21.67	320.05 ± 11.39	0.013
Perifoveal thickness
Superior	287.675 ± 19.9	286.7 ± 11.85	0.791
Inferior	279.1 ± 17.75	282.75 ± 10.34	0.264
Nasal	287.38 ± 15.82	302 ± 11.4	0.107
Temporal	278.15 ± 20.6	282.6 ± 12.144	0.243
RNFL thickness	111.4458 ± 14.6969	107.6425 ± 11.5335	0.202
GCC thickness	95.61 ± 6.385	96.1217 ± 6.1347	0.716
FLV	0.86 ± 1.04	0.60 ± 0.53	0.167
GLV	4.28 ± 3.87	3.56 ± 3.05	0.358

Independent samples -test.